A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial

Biometrics

Volumn 62, Issue 3, 2006, Pages 893-900

  Mehrotra, Devan V ^a   Li, Xiaoming ^a   Gilbert, Peter B ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Burden of illness; Causal inference; Cell mediated immunity; Fisher's test; HIV vaccine; Multiple endpoints; Principal stratification; Selection bias; Simes' test

Indexed keywords

DISEASES; LOAD TESTING; STATISTICAL TESTS;

BURDEN OF ILLNESS; CAUSAL INFERENCES; CELL-MEDIATED IMMUNITY; FISHER'S TESTS; HIV VACCINE; MULTIPLE ENDPOINT; PRINCIPAL STRATIFICATION; PROOF OF CONCEPT; SELECTION BIAS; SIMES' TEST;

VACCINES;

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

COMPARATIVE STUDY; EFFICIENCY MEASUREMENT; HUMAN IMMUNODEFICIENCY VIRUS; SIMULATION; STATISTICAL ANALYSIS; VACCINATION;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SCREENING; FISHER EXACT TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; NULL HYPOTHESIS; RANDOMIZATION; SIMULATION; STRATIFICATION; VIRUS LOAD;

EID: 33745719308     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2005.00516.x     Document Type: Article

References (25)

1. Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M., and Oldstone, M. B. (1994). Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. Journal of Virology 68, 6103-6110.
2. Burton, D. R., Desrosiers, R. C., Doms, R. W., Koffi, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A., and Wyatt, R. T. (2004). HIV vaccine design and the neutralizing antibody problem. Nature Immunology 5, 233-236.
3. Chang, M. N., Guess, H. A., and Heyse, J. F. (1994). Reduction in the burden of illness: A new efficacy measure for prevention trials. Statistics in Medicine 13, 1807-1814.
4. Cuzick, J. (1982). The efficiency of the proportions test and the log rank test for censored survival data. Biometrics 38, 1033-1039.
5. Fisher, R. A. (1932). Statistical Methods for Research Workers. Edinburgh and London: Oliver and Boyd.
6. Follmann, D. (1995). Multivariate tests for multiple endpoints in clinical trials. Statistics in Medicine 14, 1163-1175.
7. Frangakis, C. E. and Rubin, D. B. (2002). Principal stratification in causal inference. Biometrics 58, 21-29.
8. Gilbert, P. B., Bosch, R. J., and Hudgens, M. G. (2003a). Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics 59, 531-541.
9. Gilbert, P. B., DeGruttola, V., Hudgens, M. G., Self, S. G., Hammer, S. M., and Corey, L. (2003b). What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: Issues involving surrogate endpoints in phase III trials. Journal of Infectious Diseases 188, 179-193.
10. Good, I. J. (1955). On the weighted combination of significance tests. Biometrika 42, 264-265.
11. Graham, B. S. (2002). Clinical trials of HIV vaccines. Annual Review of Medicine 53, 207-221.
12. Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75, 800-802.
13. Hochberg, Y. and Liberman, U. (1994). An extended Simes test. Statistics and Probability Letters 21, 101-105.
14. Hudgens, M. G., Hoering, A., and Self, S. G. (2003). On the analysis of viral load endpoints in HIV vaccine trials. Statistics in Medicine 22, 2281-2298.
15. Lachenbruch, P. A. (2001). Comparison of two-part models with competitors. Statistics in Medicine 20, 1215-1234.
16. Mehrotra, D. V., Li, X., and Gilbert, P. B. (2005). Dual-endpoint evaluation of vaccine efficacy - Application to a proof-of-concept clinical trial of a cell mediated immunity-based HIV vaccine. BARDS Technical Report 111, Merck Research Laboratories, Blue Bell, Pennsylvania.
17. O'Brien, P. C. (1984). Procedures for comparing samples with multiple endpoints. Biometrics 40, 1079-1087.
18. Pocock, S. J., Geller, N. L., and Tsiatis, A. A. (1987). The analysis of multiple endpoints in clinical trials. Biometrics 43, 487-498.
19. The rgp120 HIV Vaccine Study Group. (2005). Placebo-controlled trial of a recombinant glycoprotein 120 vaccine to prevent HIV infection. Journal of Infectious Diseases 191, 654-665.
20. Robins, J. M. and Greenland, S. (1992). Identifiability and exchangeability of direct and indirect effects. Epidemiology 3, 143-155.
21. Rubin, D. B. (1974). Estimating causal effects of treatments in randomized and nonrandomized studies. Journal of Educational Psychology 66, 688-701.
22. Shih, W. J. and Quan, H. (1997). Testing for treatment differences with dropouts present in clinical trials - A composite approach. Statistics in Medicine 16, 1225-1239.
23. Shiver, J. W., Fu, T.-M., Chen, L., et al. (2002). Replication- incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 415, 331-335.
24. Simes, R. J. (1986). An improved Bonferroni procedure for multiple tests of significance. Biometrika 73, 751-754.
25. UNAIDS. (2004). Joint United Nations Programme for HIV/AIDS. AIDS Epidemic Update 2004. http://www.unaids.org/bangkok2004/report.html.